Given its dual role in immune regulation and tumor progression, IGSF11 holds promise as a predictive biomarker for checkpoint inhibitor responsiveness, as well as a prognostic marker for cancer aggressiveness, and potentially also for immune landscape characterization. Here, IGSF11 is linked to neoplasm.